NCT06351124View on ClinicalTrials.gov

Beta-Hydroxybutyrate Feasibility Treating IBD

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

December 31, 2025

Conditions
Crohn's DiseaseInflammatory Bowel Diseases
Interventions
BIOLOGICAL

Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's

Is Beta-hydroxybutyrate a supplement that can control symptoms and progression of Crohn's.

Trial Locations (1)

78712

RECRUITING

University of Texas at Austin, Austin

All Listed Sponsors
lead

University of Texas at Austin

OTHER